{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non+Squamous%2C+Non-small-cell+Lung+Cancer&page=18",
    "query": {
      "condition": "Non Squamous, Non-small-cell Lung Cancer",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 750,
    "total_pages": 75,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non+Squamous%2C+Non-small-cell+Lung+Cancer&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non+Squamous%2C+Non-small-cell+Lung+Cancer&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T07:41:04.265Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07221474",
      "title": "A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Intismeran Autogene",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2025-12-12",
      "completion_date": "2031-05-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-15T07:41:04.265Z",
      "location_count": 11,
      "location_summary": "Tampa, Florida • Ann Arbor, Michigan • St Louis, Missouri + 8 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Paramus",
          "state": "New Jersey"
        },
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07221474"
    },
    {
      "nct_id": "NCT03215810",
      "title": "Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Metastatic Non-small Cell Lung Cancer",
        "Squamous Cell Carcinoma",
        "Advanced NSCLC",
        "Adenosquamous Carcinoma",
        "Adenocarcinomas"
      ],
      "interventions": [
        {
          "name": "Tumor-infiltrating Lymphocytes (TIL)",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Tumor-infiltrating Lymphocyte Therapy",
          "type": "OTHER"
        },
        {
          "name": "Interleukin-2 (IL2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-10-11",
      "completion_date": "2023-06-09",
      "has_results": true,
      "last_update_posted_date": "2023-07-24",
      "last_synced_at": "2026-10-15T07:41:04.265Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • Tampa, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03215810"
    },
    {
      "nct_id": "NCT02370303",
      "title": "A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lung Cancer",
        "Lung Neoplasms",
        "Cancer of Lung",
        "Cancer of the Lung",
        "Neoplasms, Lung",
        "Neoplasms, Pulmonary",
        "Pulmonary Cancer",
        "Pulmonary Neoplasms",
        "Carcinoma, Non-small-cell Lung",
        "Adenocarcinoma",
        "Squamous Cell Carcinoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2014-08",
      "completion_date": "2016-07-09",
      "has_results": false,
      "last_update_posted_date": "2018-03-21",
      "last_synced_at": "2026-10-15T07:41:04.265Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02370303"
    },
    {
      "nct_id": "NCT05651022",
      "title": "Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "HCC - Hepatocellular Carcinoma",
        "CRC (Colorectal Cancer)",
        "Pancreatic Adenocarcinoma",
        "NSCLC Non-small Cell Lung Cancer",
        "Squamous Cell Cancer of the Head and Neck",
        "UC (Urothelial Cancer)",
        "MSI-H Cancer"
      ],
      "interventions": [
        {
          "name": "Decoy20",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indaptus Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2023-02-28",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-10-15T07:41:04.265Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05651022"
    },
    {
      "nct_id": "NCT04432207",
      "title": "A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Non Small Cell Lung Cancer Stage IIIB",
        "Non-small Cell Lung Cancer Stage IV",
        "Squamous Non-small-cell Lung Cancer",
        "Large Cell Carcinoma Lung",
        "Adenocarcinoma Lung"
      ],
      "interventions": [
        {
          "name": "IMU-201 (administered as PD1-Vaxx) - Regimen 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IMU-201 (administered as PD1-Vaxx) - Regimen 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IMU-201 (administered as PD1-Vaxx) - Regimen 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Standard of care chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Imugene Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2020-11-30",
      "completion_date": "2024-11-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-25",
      "last_synced_at": "2026-10-15T07:41:04.265Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Hackensack, New Jersey • Columbus, Ohio",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04432207"
    },
    {
      "nct_id": "NCT00538850",
      "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Fentanyl sublingual spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "INSYS Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2007-10",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2014-03-05",
      "last_synced_at": "2026-10-15T07:41:04.265Z",
      "location_count": 1,
      "location_summary": "Chandler, Arizona",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538850"
    },
    {
      "nct_id": "NCT03845296",
      "title": "Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Deleterious BRCA1 Gene Mutation",
        "Deleterious BRCA2 Gene Mutation",
        "Loss of Heterozygosity",
        "Lung Non-Small Cell Squamous Carcinoma",
        "Recurrent Large Cell Lung Carcinoma",
        "Recurrent Lung Adenocarcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Recurrent Non-Squamous Non-Small Cell Lung Carcinoma",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Rucaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 64,
      "start_date": "2019-04-16",
      "completion_date": "2024-09-21",
      "has_results": true,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-10-15T07:41:04.265Z",
      "location_count": 950,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03845296"
    },
    {
      "nct_id": "NCT02988960",
      "title": "A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors Cancer"
      ],
      "interventions": [
        {
          "name": "ABBV-927",
          "type": "DRUG"
        },
        {
          "name": "ABBV-181",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 163,
      "start_date": "2017-02-22",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-15T07:41:04.265Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02988960"
    },
    {
      "nct_id": "NCT02134912",
      "title": "S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Lung",
        "Large Cell Lung Cancer",
        "Recurrent Non-small Cell Lung Cancer",
        "Stage IV Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "crizotinib",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed disodium",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2014-08",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2020-02-20",
      "last_synced_at": "2026-10-15T07:41:04.265Z",
      "location_count": 167,
      "location_summary": "Sacramento, California • Aurora, Colorado • Colorado Springs, Colorado + 111 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02134912"
    },
    {
      "nct_id": "NCT03758781",
      "title": "IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Recurrent Cancer",
        "Solid Tumor",
        "Renal Cell Carcinoma",
        "Urothelial Carcinoma",
        "NSCLC",
        "Squamous Cell Carcinoma",
        "Non-Small Cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "IRX 2",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2019-02-13",
      "completion_date": "2021-08-11",
      "has_results": false,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-10-15T07:41:04.265Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03758781"
    }
  ]
}